Autolomous, Cellular Origins Expand Platform Integration, Enabling End-to-End Cell Therapy Manufacturing

Editor’s Take: End-to-end integration gives developers greater standardization, traceability, and control across the entire process.

Autolomous and Cellular Origins have fully integrated their respective platforms end to end, automating and digitizing cell therapy manufacturing processes.

Cellular Origins, Autolomous Platforms

By design, Cellular Origins’ Constellation automated platform enables low-risk cell therapy manufacturing. It has a flexible, modular architecture harmonizing mobile robotics, previously existing bioprocessing technologies, and sterile fluid transfer.

Meanwhile, Autolomous’ digital autoloMATE platform exchanges data in real time, looping in existing software, AI systems, devices, and robotic platforms. autoloMATE safeguards intellectual property, permitting configuration of deployments to customer needs.

How They Work Together

Combined, these solutions overcome fragmentation, limited visibility, and absence of standardized data flows without replacing existing processes. This allows manufacturers to scale to commercially viable levels, reducing scale-up risk and the need for therapy redevelopment. Overall, the approach fosters a connected manufacturing environment giving developers greater standardization, traceability, and control across the process.

“Scientific ambition has never been the bottleneck in bringing innovative cell therapy to patients,” Autolomous CEO Alexander Seyf said. “But the delivery infrastructure has brought many challenges. Together with Cellular Origins, we enable fast, efficient scaling from research through to patient administration, ensuring standardization, automation and digitization.”

“Scaling cell therapy manufacturing is not just a question of employing automation,” Cellular Origins CEO Edwin Stone said. “It requires a manufacturing system that can evolve with demand. Our collaboration with Autolomous—and the Cell and Gene Therapy Catapult—demonstrates how robotic platforms and digital infrastructure operate as one.”

In an InnovateUK-funded project, first integrations were already achieved at the Cell and Gene Therapy Catapult Digital and Automation Testbeds.